Saturday, September 03, 2016 7:04:31 PM
Ok, maybe that's a bit over the top as a headline. :)
Well, perhaps a bit of sensationalism is warranted to compete with all the current media hooplah over Anavex's competitor Biogen. Biogen's amyloid shattering therapy is being hailed as some kind of amazing breakthrough. I seriously doubt that it's anything of the sort. In fact, the currently fashionable "war on amyloid", displacing cholinesterase inhibitors as the industry darling, is ill conceived. It's all based on early total acceptance of the "amyloid hypothesis" which is also looking ill advised. imo
After one of the previous bubbles burst, there were all these brand new office buildings, unoccupied. Nobody to rent office space. Yet construction continued on more. Why? Because contracts had been signed. They had to be finished. I think something like that sometimes happens in (big) bio-tech. Amyloid plaques are discovered. The conclusion is jumped to that it is the cause of the disease. Now a space race to the moon is launched. Billions are committed to get rid of the nasty amyloid, who will be first. They have to finish. Meanwhile guys like the research below indicating a contrary result apparently didn't get any more funding.
Found this research article from a few years that confirms my scepticism about getting rid of all the amyloid.
"Guardian Amyloid?
http://www.alzforum.org/news/research-news/guardian-amyloid-av-hexamers-help-multiple-sclerosis-mouse-model
Amyloid is an electrical insulator, just like the myelin sheath around axons. The sheath is composed of flat Schwann cells which wrap themselves around the axon like wrapping paper around a wire. They are mostly lipid (a kind of fat) which isn't known for being sturdy, but their main function is to insulate. This allows charge to build up underneath which speeds the action pulses on their way to the next neuron must faster than without. Damaged insulation is a characteristic of Multiple Sclerosis.
Although the new plaque therapy is better than reformulated painter remover as I initially feared, I'm not sure if it really is that much better. I also previously joked about yet another bizarre new therapy being announced that involved training brain-eating amoebae to eat amyloid. Seems I wasn't so far off. Microglial cells in the brain, which normally perform cleanup duty at a leasuirely pace, have different modes and can tranform themselves as required including an amoeboid form. Go figure. :)
The new therapy involves tagging amyloid which stimulates the microglia into becoming a hoard of amyloid devouring berserkers. OK, so we have some amyloid stuck on an axon. Is it possible that some of the flavor has imprinted on the myelin, what if our newly energetic little packmen start chomping on that? My other concern relates to the idea that AD may be caused by errant immune response. In which case we would want to calm things down, not add to the mayhem. (aka Anavex 2-73)
Oh well. Time will tell who is more right...
Recent AVXL News
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:05:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:06 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:31:07 PM
- Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/07/2024 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024 • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:01:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM